Novel antioxidants in anthracycline cardiotoxicity

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 160-164

  Hideg, Kálmán ^a   Kálai, Tamás ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Anthracyclines; Antioxidants; Cardiomyopathy; EPR; Free radicals; Nitroxides

Indexed keywords

ANTHRACYCLINE; ANTIOXIDANT; DAUNORUBICIN; DOXORUBICIN; H 2545; H 2954; NITROXIDE DERIVATIVE; TEMPOL; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CONFERENCE PAPER; DRUG STRUCTURE; HEART PROTECTION; HUMAN; LIPID PEROXIDATION; NONHUMAN; PREVENTION; PRIORITY JOURNAL;

AMINES; ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CYCLIC N-OXIDES; HEART DISEASES; HUMANS; NITROGEN OXIDES; SPIN LABELS;

EID: 34548336831     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0019-z     Document Type: Conference Paper

References (25)

1. Ross, W. E., Glaubiger, D. L., & Kohn, K. W. (1978). Protein associated DNA breaks in cells treated with adriamycin or ellipticine. Biochimica et Biophysica Acta, 519, 23-30.
2. Hertzberg, R. P., & Dervan, P. B. (1984). Clevage of DNA with methidiumpropyl-EDTA-Iron(II)-reaction conditions and procuct analyses. Biochemistry, 23, 3934-3945.
3. Walling, C. (1975). Fenton's reagent revisited. Accounts of Chemical Research, 8, 125-131.
4. Hasinoff, B. B., Kuschak, T. I., Jalowich, J. C., & Creighton, A. M. (1995). A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (Dexrazoxane). Biochemical Pharmacology, 50, 953-958.
5. Wiseman, L. R., & Spencer, C. M. (1998). Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs, 56, 385-403.
6. Swenson, C. E., Bolcsak, L. E., Batist, G., Guthrie, T. H., Tkaczuk, K. H., Boxenbaum, H., Welles, L., Show, S. C., Bhamra, R., & Chakin, P. (2003). Pharmacokinetics of doxorubicin administered i.v. as myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anti-Cancer Drugs, 14, 239-246.
7. Abou El Hassan, M. A. I., Kedde, M. A., Zwiers, U. T. H., Tourn, E., Haennen, G. R. M., Bast, A., & van der Vijgh, W. J. F. (2003). Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. Cancer Chemotherapy and Pharmacology, 52, 371-376.
8. Monti, E., Cova, D., Guido, E., Morelli, R., & Oliva, C. (1996). Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radical Biology and Medicine, 21, 463-470.
9. DeGraff, W., Hahn, S. M., Mitchell, J. B., & Krishna, M. C. (1994). Free radical modes of cytotoxicity of adriamycin® and streptonigrin. Biochemical Pharmacology, 48, 1427-1435.
10. Hankovszky, H. O., Hideg, K., Bódi, I., & Frank, L. (1986). New Antiarrhythmic Agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethyl-pyrrolidine-3-carboxamides. Journal of Medicinal Chemistry, 29, 1138-1152.
11. Twomey, P., Taira, J., DeGraff, W., Mitchell, J. B., Russo, A., Krishna, M. C., Hankovszky, H. O., Frank, L., & Hideg, K. (1997). Direct evidence for In Vivo nitroxide free radical production from a new antiarrhythic drug by EPR spectroscopy. Free Radical Biology and Medicine, 22, 909-916.
12. Shankar, R.A., Hideg, K., Zweier, J. L., & Kuppusamy, P. (2000). Targeted antioxidant properties of N-[(Tetramethyl-3-pyrroline-3- carboxamido) propylphthalimide, a new antiarrhythmic drug and its nitroxide-metabolite in preventing postischemic myocardial injury. Journal of Pharmacology and Experimental Therapeutics, 292, 838-845.
13. Marton, Zs., Halmosi, R., Horváth, B., Alexy, T., Késmárky, G., Vékási, J., Battyány, I., Hideg, K., & Tóth, K. (2001). Scavenger effect of experimental and clinically used cardiovascular drugs. Journal of Cardiovascular Pharmacolgy, 38, 745-753.
14. Deres, P., Halmosi, R., Tóth, A., Kovács, K., Pálfi, A., Habon, T., Czopf, L., Kálai, T., Hideg, K., Sümegi, B., & Tóth, K. (2005). Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. Journal of Cardiovascular Pharmacology, 45, 36-43.
15. Mordente, A., Meucci, E. , Martorana, G. E., Giardina, B., & Minotti, G. (2001). Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life, 52, 83-88.
16. Kálai, T., Hideg, É., Vass, I. & Hideg, K. (1998) Double (Fluorescent and Spin) Sensors for detection of reactive oxygen species in the thylakoid membrane. Free Radical Biology and Medicine, 24, 649-652.
17. .- or as SOD mimics? Journal of Biological Chemistry, 271, 26026-26031.
18. Goldstein, S., Samuni, A., Hideg, K., & Merényi, G. (2006). Structure-activity relationship of cyclic nitroxides as SOD mimics and scavengers of nitrogen dioxide and carbonate radicals. Journal of Physical Chemistry A, 110, 3679-3685.
19. Glebska, J., Pulaski, L., Gwozdzinski, K., & Kolimowski, J. (2001). Structure-activity relationship studies of protetive function of nitroxides in Fenton system. BioMetals, 14, 159-170.
20. Zhang, R., Hirsch, O., Mohsen, M., & Samuni, A. (1994). Effects of nitroxide stable radicals on juglone cytotoxicity. Archives of Biochemistry and Biophysics, 312, 385-391.
21. Li, H., Xu, K. Y., Zhou, L., Kálai, T., Zweier, J. L., Hideg, K., & Kuppusamy, P. (2000). A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion- induced myocardial contractile dysfunction. Journal of Pharmacology and Experimental Therapeutics, 295, 563-571.
22. Bognár, Z., Kálai, T., Pálfi, A., Hantó, K., Bognár, B., Márk, L., Szabó, Z., Tapodi, A., Radnai, B., Sárszegi, Zs., Szántó, Á. Jr., Gallyas, F., Hideg, K., Sümegi, B., & Várbíró, G. (2006). A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death. Free Radical Biology and Medicine, 41, 835-848.
23. Kutala, V. K., Khan, M., Mandal, R., Ganesan, L. P., Tridandapani, S., Kálai, T., Hideg, K., & Kuppusamy, P. (2006). Attenuation of myocardial ischemia-reperfusion injury by trimetazidine derivatives functionalized with antioxidant properties. Journal of Pharmacology and Experimental Therapeutics, 317, 921-928.
24. Kálai, T., Mugesh, G., Roy, G., Sies, H., Berente, Z., & Hideg, K. (2005). Combining benzol[d]isoselenazol-3-ones with sterically hindered alicyclic amines and nitroxides: enhanced activity as glutathione peroxidase mimics. Organic Biomolecular Chemistry, 3, 3564-3569.
25. 3+ complexes of three spin labeled DTPA-bis(amide) derivative ligands. European Journal of Inorganic Chemistry, 2003, 3601-3608.